These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 2395825)

  • 1. [The use of the antipyrine test in assessing liver function in patients with insulin-dependent diabetes mellitus].
    Khanina EV; Gorshteĭn ES; Michurina SP
    Probl Endokrinol (Mosk); 1990; 36(3):14-5. PubMed ID: 2395825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saliva and plasma clearance of antipyrine as reflectors of liver function.
    Luoma PV; Sotaniemi EA
    Eur J Drug Metab Pharmacokinet; 1981; 6(4):261-4. PubMed ID: 7333326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement.
    Sotaniemi EA; Pelkonen O; Arranto AJ; Tapanainen P; Rautio A; Pasanen M
    Pharmacol Toxicol; 2002 Mar; 90(3):155-60. PubMed ID: 12071338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic drug metabolism is increased in poorly controlled insulin-dependent diabetes mellitus.
    Goldstein S; Simpson A; Saenger P
    Acta Endocrinol (Copenh); 1990 Nov; 123(5):550-6. PubMed ID: 2256435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antipyrine clearance as a measure of drug metabolism in patients with diabetes mellitus].
    Oltmanns D; Dennin DE; Pentz R; Siegers CP
    Z Gastroenterol; 1984 Oct; 22(10):598-601. PubMed ID: 6506825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Galactose and antipyrine load tests in assessing the detoxification activity of the liver].
    Maestri G; D'Amore V; Angeli E
    Minerva Dietol Gastroenterol; 1979; 25(4):399-406. PubMed ID: 554030
    [No Abstract]   [Full Text] [Related]  

  • 7. [Evaluation of metabolic efficiency of the liver in patients with psoriasis by the antipyrine test].
    Bienias L; Czarnecki M; Kaszuba A; Ruszczak Z; Kozłowska M; Bednarowicz G; Drobnik G
    Przegl Dermatol; 1990; 77(5):301-6. PubMed ID: 2270292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of the metabolizing function of the liver in thyrotoxicosis using the antipyrine test].
    Salakhova NS; Nazhmutdinova DK
    Probl Endokrinol (Mosk); 1987; 33(1):9-11. PubMed ID: 3823028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipyrine metabolism and liver function in patients treated with high-dose medroxyprogesterone.
    Rautio A; Kauppila AJ; Tuimala RJ; Sotaniemi EA
    Biomedicine; 1979 Sep; 31(5):135-8. PubMed ID: 508896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evaluation of the drug-metabolizing capacity in patients with diabetes mellitus.
    Salmela PI; Sotaniemi EA; Pelkonen RO
    Diabetes; 1980 Oct; 29(10):788-94. PubMed ID: 7439538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antitoxic function of the liver and the effect of zixorin in patients with diabetes mellitus].
    Geller LI; Griaznova MV
    Probl Endokrinol (Mosk); 1987; 33(4):9-10. PubMed ID: 3658956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipyrine kinetics in undernourished diabetics.
    Shobha JC; Raghuram TC; Kumar AD; Krishnaswamy K
    Eur J Clin Pharmacol; 1991; 41(4):359-61. PubMed ID: 1804653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of subchronic treatment with natural human interferons on antipyrine clearance and liver function in patients with chronic hepatitis.
    Echizen H; Ohta Y; Shirataki H; Tsukamoto K; Umeda N; Oda T; Ishizaki T
    J Clin Pharmacol; 1990 Jun; 30(6):562-7. PubMed ID: 2113064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipyrine clearance in comparison to conventional liver function tests in hepatitis C virus patients.
    Mahmoud M; Abdel-Kader R; Hassanein M; Saleh S; Botros S
    Eur J Pharmacol; 2007 Aug; 569(3):222-7. PubMed ID: 17628532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effect of type I and type II diabetes mellitus on antipyrine elimination.
    Adithan C; Danda D; Shashindran CH; Bapna JS; Swaminathan RP; Chandrasekar S
    Methods Find Exp Clin Pharmacol; 1989 Dec; 11(12):755-8. PubMed ID: 2626081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dynamics of antipirin test at patients with alcoholic liver disease on the background of metadoksin drug receiving].
    Sil'vestrova SIu; Fedotova SIu; Drozdov TF; Petrakov AV
    Eksp Klin Gastroenterol; 2011; (6):32-7. PubMed ID: 22168075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The antipyrine test in occupational medicine research--evaluation of individual reproducibility and frequency distribution of half-life].
    Uhlig H; Damrau J; Skölziger R
    Z Gesamte Hyg; 1989 Feb; 35(2):82-4. PubMed ID: 2741499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impairment of drug elimination in patients with liver disease.
    Narang AP; Datta DV; Mathur VS
    Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):28-32. PubMed ID: 3988389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [An attempt at assessment of biotransformation activity in calves' liver on the basis of the rate of antipyrine elimination from saliva].
    Janus K; Baranow-Baranowski S; Jakubowska D
    Pol Arch Weter; 1991; 31(3-4):65-71. PubMed ID: 1842615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Quantification of the drug-metabolizing enzyme system in liver diseases: a comparison between antipyrine saliva clearance and the aminopyrine breath test].
    von Mandach U; Jost G; Preisig R
    Schweiz Med Wochenschr; 1985 May; 115(19):651-8. PubMed ID: 3923620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.